Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

NCT04684472 is registered in ClinicalTrials.gov with Liqun Zou as lead sponsor.

NCT NCT04684472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Lead sponsor
Liqun Zou
Phase
Phase 1
Overall status
Unknown status
Start date
March 17, 2021
Completion date
January 1, 2024
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell non-hodgkin lymphoma, refractory leukemia